| Revision as of 01:50, 28 May 2019 editThe Nth User (talk | contribs)Extended confirmed users8,433 edits →References: Added one category← Previous edit |
Revision as of 17:12, 20 January 2020 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,799 edits consistent citation formattingNext edit → |
| Line 38: |
Line 38: |
|
| StdInChIKey = BDABGOLMYNHHTR-UHFFFAOYSA-N |
|
| StdInChIKey = BDABGOLMYNHHTR-UHFFFAOYSA-N |
|
}} |
|
}} |
|
'''Perzinfotel''' ('''EAA-090''') is a drug which acts as a potent ].<ref>{{cite journal | pmid = 9457246 | doi=10.1021/jm970504g | volume=41 | title=Design and synthesis of non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere | date=January 1998 | journal=J. Med. Chem. | pages=236–46 | last1 = Kinney | first1 = WA | last2 = Abou-Gharbia | first2 = M | last3 = Garrison | first3 = DT |display-authors=etal }}</ref> It has ] effects and has been investigated for the treatment of ],<ref>{{cite journal | last1 = Sun | first1 = L | last2 = Chiu | first2 = D | last3 = Kowal | first3 = D | last4 = Simon | first4 = R | last5 = Smeyne | first5 = M | last6 = Zukin | first6 = RS | last7 = Olney | first7 = J | last8 = Baudy | first8 = R | last9 = Lin | first9 = S | date = Aug 2004 | title = Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride) | url = | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 310 | issue = 2| pages = 563–70 | doi = 10.1124/jpet.104.066092 | pmid = 15075380 }}</ref> but lacks ] effects.<ref>{{cite journal | pmid = 15764736 | doi=10.1124/jpet.105.084467 | volume=313 | title=Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity | date=June 2005 | journal=J. Pharmacol. Exp. Ther. | pages=1379–86 | last1 = Brandt | first1 = MR | last2 = Cummons | first2 = TA | last3 = Potestio | first3 = L | last4 = Sukoff | first4 = SJ | last5 = Rosenzweig-Lipson | first5 = S}}</ref> Nevertheless, it shows a good safety profile compared to older drugs, although further development of this drug has been discontinued.<ref>http://adisinsight.springer.com/drugs/800009946</ref> |
|
'''Perzinfotel''' ('''EAA-090''') is a drug which acts as a potent ].<ref>{{cite journal | vauthors = Kinney WA, Abou-Gharbia M, Garrison DT, Schmid J, Kowal DM, Bramlett DR, Miller TL, Tasse RP, Zaleska MM, Moyer JA | display-authors = 6 | title = Design and synthesis of non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 2 | pages = 236–46 | date = January 1998 | pmid = 9457246 | doi = 10.1021/jm970504g }}</ref> It has ] effects and has been investigated for the treatment of ],<ref>{{cite journal | vauthors = Sun L, Chiu D, Kowal D, Simon R, Smeyne M, Zukin RS, Olney J, Baudy R, Lin S | display-authors = 6 | title = Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride) | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 310 | issue = 2 | pages = 563–70 | date = August 2004 | pmid = 15075380 | doi = 10.1124/jpet.104.066092 }}</ref> but lacks ] effects.<ref>{{cite journal | vauthors = Brandt MR, Cummons TA, Potestio L, Sukoff SJ, Rosenzweig-Lipson S | title = Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 313 | issue = 3 | pages = 1379–86 | date = June 2005 | pmid = 15764736 | doi = 10.1124/jpet.105.084467 }}</ref> Nevertheless, it shows a good safety profile compared to older drugs, although further development of this drug has been discontinued.<ref>{{cite web | title = Perzinfotel | url = http://adisinsight.springer.com/drugs/800009946 | work = Adis International Ltd. | publisher = Springer Nature Switzerland AG }}</ref> |
|
|
|
|
|
Prodrugs were developed since the oral bioavailability of perzinfotel is only around 3-5%.<ref name="BaudyButera2009">{{cite journal|last1=Baudy|first1=Reinhardt B.|last2=Butera|first2=John A.|last3=Abou-Gharbia|first3=Magid A.|last4=Chen|first4=Hong|last5=Harrison|first5=Boyd|last6=Jain|first6=Uday|last7=Magolda|first7=Ronald|last8=Sze|first8=Jean Y.|last9=Brandt|first9=Michael R.|last10=Cummons|first10=Terri A.|last11=Kowal|first11=Diane|last12=Pangalos|first12=Menelas N.|last13=Zupan|first13=Bojana|last14=Hoffmann|first14=Matthew|last15=May|first15=Michael|last16=Mugford|first16=Cheryl|last17=Kennedy|first17=Jeffrey|last18=Childers|first18=Wayne E.|title=Prodrugs of Perzinfotel with Improved Oral Bioavailability|journal=Journal of Medicinal Chemistry|volume=52|issue=3|year=2009|pages=771–778|issn=0022-2623|doi=10.1021/jm8011799|pmid=19146418}}</ref> |
|
Prodrugs were developed since the oral bioavailability of perzinfotel is only around 3-5%.<ref name="BaudyButera2009">{{cite journal | vauthors = Baudy RB, Butera JA, Abou-Gharbia MA, Chen H, Harrison B, Jain U, Magolda R, Sze JY, Brandt MR, Cummons TA, Kowal D, Pangalos MN, Zupan B, Hoffmann M, May M, Mugford C, Kennedy J, Childers WE | display-authors = 6 | title = Prodrugs of perzinfotel with improved oral bioavailability | journal = Journal of Medicinal Chemistry | volume = 52 | issue = 3 | pages = 771–8 | date = February 2009 | pmid = 19146418 | doi = 10.1021/jm8011799 }}</ref> |
|
|
|
|
|
== References == |
|
== References == |
Prodrugs were developed since the oral bioavailability of perzinfotel is only around 3-5%.
